Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium, the active ingredient in Neodolpasse, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an intravenous solution for intravenous use. It, together with orphenadrine citrate, is employed to manage pain, inflammation, and muscle spasm in adult patients in both acute and chronic clinical settings.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide across Europe, Asia, Africa and the Americas, with a focus on quality assurance and regulatory compliance.

Neodolpasse combines an NSAID and a central muscle relaxant to address conditions involving pain, inflammation, and muscle spasm.

- Acute postoperative pain: provides rapid analgesia and reduces inflammatory response, facilitating early mobilization after surgery. - Musculoskeletal inflammation: decreases swelling and pain in conditions such as sprains, strains, and arthritic flare‑ups, improving joint function. - Muscle spasm associated with orthopedic injuries: relaxes skeletal muscle tone and alleviates discomfort, supporting physiotherapy and rehabilitation.

Neodolpasse may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in some patients. - Headache: transient headache reported after infusion. - Dizziness: occasional light‑headedness during or after administration. - Injection site pain: local discomfort at the IV site. - Mild hypotension: transient drop in blood pressure. - Transient liver enzyme elevation: mild, reversible changes.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Gastrointestinal bleeding: risk of ulceration or hemorrhage, especially with concurrent NSAIDs. - Hepatic injury: potential for serious liver dysfunction. - Renal impairment: acute kidney injury in susceptible individuals. - Cardiovascular events: increased risk of myocardial infarction or stroke. - Neutropenia: rare reduction in white blood cell count.

Neodolpasse should be used with careful clinical assessment and monitoring. - Renal function: assess baseline renal status and monitor during therapy. - Hepatic function: use with caution in patients with liver disease. - Cardiovascular risk: avoid in patients with uncontrolled hypertension or heart failure. - Bleeding risk: monitor for signs of gastrointestinal bleeding, especially with concurrent anticoagulants. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Neodolpasse may interact with several drug classes; clinicians should review patient medication profiles.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: diclofenac may raise lithium serum levels. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may diminish renal function. - Diuretics: heightened risk of renal impairment. - Corticosteroids: increased likelihood of gastrointestinal ulceration.